MétaCan
Menu
Back to cohort
Record W2567549055 · doi:10.1016/s1525-0016(16)33172-0

363. Improvement of Sandhoff Phenotype Following Intravenous Injection of Adeno-Associated Viral Vector Expressing a Hexosaminidase Isoenzyme in Adult Sandhoff Mice: Preclinical Safety and Efficacy Study

2016· article· en· W2567549055 on OpenAlexaff
Karlaina J.L. Osmon, Evan Woodley, Patrick Thompson, Subha Karumuthil‐Melethil, Steven J. Gray, Jagdeep S. Walia

Bibliographic record

VenueMolecular Therapy · 2016
Typearticle
Languageen
FieldMedicine
TopicLysosomal Storage Disorders Research
Canadian institutionsQueen's University
Fundersnot available
KeywordsSandhoff diseaseHexosaminidaseGangliosidosisHEXABiologyProtein subunitPharmacologyInternal medicineImmunologyEndocrinologyMolecular biologyMedicineBiochemistryEnzymeGene

Abstract

fetched live from OpenAlex

GM2 gangliosidosis disorders stem from a Hexosaminidase A (HexA) isoenzyme deficiency. In humans, HexA is the sole enzyme able to catabolize GM2 ganglioside (GM2). The inability to effectively catabolize GM2 leads to neurodegeneration of the central nervous system. HexA is comprised of 2 subunits (α, β) and works with the GM2 activator protein (GM2AP). In the recent work by Tropak et al. (Mol Ther Met Clin Dev, in press), a hybrid subunit, named µ-subunit, was created (patent pending) by combining the stabilization and GM2AP binding sites of the β-subunit while conserving the catalytic properties of the α-subunit. The ‘µ’-subunit, coded by HEXM, can homodimerize and form a stable, functional enzyme, named HexM, which can interact with GM2AP to hydrolyse GM2. Previous work for successful correction of Sandhoff mice using AAV was only shown in neonatal mice (with immature blood-brain barrier (BBB)) and may not directly help in designing a human clinical trial. In the current study, we examined the efficacy/safety of IV injections of the scAAV9/HEXM vector at two doses in adult SD mice (with mature BBB). In addition, we also tested if an adjunct IV injection of mannitol provides any enhancement in efficacy. At 6 weeks old, the vector was injected via tail vein in cohorts of n=17 and n=15 SD mice at 2.5E+12 or 1.0E+13 vg/mouse, respectively. Another cohort of 16 mice received IV mannitol (3g/kg) prior to an IV injection of 2.5E+12 vg scAAV9/HEXM. Some mice from low dose group were euthanized at 16 weeks for direct analysis with untreated SD control mice, while the remainder were left until for terminal survival. Analysis of survival benefit, locomotor behaviour, biochemical and molecular parameters were performed. While untreated SD mice had a 16 week humane endpoint, 4 of 7 mice in higher dose group are now surviving past 56 weeks, 1 of 12 mice in the low dose cohort, and 4 of 9 mice in the mannitol cohort are surviving past 52 weeks. These increases in survival are all highly significant compared to the ~16 week humane endpoint of untreated SD mice. Behaviourally, there are no major significant differences in locomotion between the groups until after 15 weeks, when the adjunct mannitol group significantly outperforms the PBS group. Survival and behaviour monitoring, and the biochemical analyses for this study are ongoing. The preliminary results from this study show delayed onset of the SD phenotype with a single AAV9/HEXM injection and a significant benefit of a pre-injection of IV mannitol. This study is the first to show that an IV gene transfer using a scAAV/HEXM vector can provide survival and behavioural benefit in adult SD mice especially with adjunct use of mannitol. We propose that these results can advise the design of a human gene therapy trial for SD and the related Tay-Sachs disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.436
Threshold uncertainty score0.700

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.315
Teacher spread0.298 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueMolecular TherapySame topicLysosomal Storage Disorders ResearchFrench-language works237,207